Mark A. Lemmon

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Mark Lemmon
FRS
Professor Mark Lemmon FRS.jpg
Mark Lemmon at the Royal Society admissions day in London in 2016
Alma mater
Scientific career
Fields
Institutions
ThesisSpecific interactions between transmembrane alpha-helices: Their role in the oligomerisation of integral membrane proteins (1993)
Doctoral advisorDonald Engelman
Website

Mark Andrew Lemmon FRS,[2] an English-born biochemist, is the David A. Sackler professor of Pharmacology at Yale University where he co-directs the Cancer Biology Institute with Joseph Schlessinger.[1][3]

Education[edit]

Lemmon was born in Norfolk, England in 1964. He was educated first at Norwich School, and then at Hertford College, Oxford, from which he graduated with a first class Bachelor of Arts degree in Biochemistry in 1988.[3] He completed his PhD at Yale University as a Howard Hughes Medical Institute Predoctoral Fellow supervised by Donald Engelman[4] for research on the oligomerization of transmembrane α-helices.[5] Following his PhD, Lemmon was a postdoctoral researcher and fellow of the Damon Runyon Cancer Research Foundation at New York University in the laboratory of Joseph Schlessinger.[6]

Research and career[edit]

Following his postdoctoral studies, Lemmon was recruited to the Department of Biochemistry and Biophysics at the University of Pennsylvania Perelman School of Medicine, where he gained tenure in 2001 and became Departmental Chair in 2008. He remains an Adjunct Professor of Biochemistry and Biophysics at University of Pennsylvania.

Lemmon's research combines biochemistry and structural biology with cell biology, focusing on understanding molecular mechanisms of transmembrane signalling by cell-surface growth factor receptors such as the epidermal growth factor (EGF) receptor[1][2] and other receptor tyrosine kinases.[7] With Kathryn Ferguson and others, he also played an important role in understanding the structure and function of the Pleckstrin homology domain in phosphoinositide signalling and elsewhere.

Lemmon has made important contributions to the discovery of both normal and pathological activation mechanisms of growth factor receptors and the signalling networks that they engage within cells. He is also committed to exploiting this understanding clinically. These receptors and their downstream effectors are activated aberrantly in numerous cancers, and are important targets of cancer drugs. Lemmon's recent work has focused on the need to understand the biochemistry of oncogenic activation to use such drugs effectively.[2]

Before moving to Yale, Lemmon was George W. Raiziss Professor and Chair of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania.[2][8] His research has been funded by the National Cancer Institute, the National Institute of General Medical Sciences, and the Department of Defense Congressionally Directed Medical Research Programs.[6]

Lemmon serves on the editorial boards of several journals, including Cell, Molecular Cell, Molecular and Cellular Biology, and Science Signaling. He is also Associate Editor for the Biochemical Journal.[9] Between 2007 and 2013, Lemmon was Secretary of the American Society for Biochemistry and Molecular Biology.

Awards and honours[edit]

Lemmon was elected a Fellow of the Royal Society (FRS) in 2016.[2] In 2012, Lemmon won the Dorothy Crowfoot Hodgkin Award of the Protein Society.[10]

References[edit]

  1. ^ a b c d Mark A. Lemmon publications indexed by Google Scholar
  2. ^ a b c d e Anon (2016). "Professor Mark Lemmon FRS". London: Royal Society. Archived from the original on 2016-04-29. One or more of the preceding sentences incorporates text from the royalsociety.org website where:

    "All text published under the heading 'Biography' on Fellow profile pages is available under Creative Commons Attribution 4.0 International License." --"Royal Society Terms, conditions and policies". Archived from the original on 2015-09-25. Retrieved 2016-03-09.

  3. ^ a b "Mark Andrew Lemmon, PhD: David A. Sackler Professor of Pharmacology; Co-director, Cancer Biology Institute". Yale: yale.edu. Archived from the original on 2016-04-21.
  4. ^ Lemmon, Mark A.; Flanagan, John M.; Treutlein, Herbert R.; Zhang, Jian; Engelman, Donald M. (1992). "Sequence specificity in the dimerization of transmembrane .alpha.-helixes". Biochemistry. 31 (51): 12719–12725. doi:10.1021/bi00166a002. PMID 1463743.
  5. ^ Lemmon, Mark Andrew (1993). Specific interactions between transmembrane alpha-helices: Their role in the oligomerization of integral membrane proteins (PhD thesis). Yale University. (subscription required)
  6. ^ a b Mark Andrew Lemmon's Entry at ORCID
  7. ^ Lemmon, Mark Andrew; Schlessinger, Joseph (2010). "Cell Signaling by Receptor Tyrosine Kinases". Cell. 141 (7): 1117–1134. doi:10.1016/j.cell.2010.06.011. PMC 2914105. PMID 20602996.
  8. ^ "Mark Andrew Lemmon". Pennsylvania: upenn.edu. Archived from the original on 2016-05-16.
  9. ^ "Home - Biochemical Journal". www.biochemj.org.
  10. ^ http://www.proteinsociety.org/protein-society-awards/the-dorothy-crowfoot-hodgkin-award/